Skip to main content

BRIEF RESEARCH REPORT article

Front. Immunol.
Sec. Alloimmunity and Transplantation
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1501813

Severe metabolic accumulation of VV116 in kidney transplant patients with impaired renal function: A Case Series Report

Provisionally accepted
Jiaying Zhang Jiaying Zhang 1Yuan Gao Yuan Gao 2Xiaoyun Miao Xiaoyun Miao 3Wei Wang Wei Wang 4Zhongkai Zhou Zhongkai Zhou 4Yunyi Gao Yunyi Gao 5Liwei Liu Liwei Liu 2Menghua Wu Menghua Wu 6Ke Ma Ke Ma 7Ling Zhou Ling Zhou 7Yan Yang Yan Yang 7Sha Meng Sha Meng 8Yingmei Feng Yingmei Feng 8Zhuorui Zhao Zhuorui Zhao 9Wei Liu Wei Liu 10Danlei Mou Danlei Mou 1Zixin Kang Zixin Kang 1Lianchun Liang Lianchun Liang 1Zhongjie Hu Zhongjie Hu 11*
  • 1 Department of Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, Beijing, China
  • 2 Fourth Department of Liver Disease, Beijing You’An Hospital, Capital Medical University, Beijing, China., Beijing, China
  • 3 Department of Critical Care Medicine, Cangzhou Central Hospital, Hebei, China., Hebei, China
  • 4 Department of Radiology, Beijing Youan Hospital, Capital Medical University, Beijing, China
  • 5 Safe Transfusion Lab, Beijing Red Cross Blood Center, Beijing, China
  • 6 Department of Urology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
  • 7 Department of Bioanalysis, United-Power Pharma Tech Co., Ltd, Shanghai, China
  • 8 Department of Science and Technology, Beijing You’An Hospital, Capital Medical University, Beijing, China
  • 9 Xenorm MedInfo Center, Beijing, China
  • 10 Department of Pharmacy, Beijing Youan Hospital, Capital Medical University, Beijing, China
  • 11 Liver Disease Center, Beijing You’An Hospital, Capital Medical University, Beijing, China

The final, formatted version of the article will be published soon.

    The treatment of COVID-19 in the post-transplant individuals is challenging, primarily due to the drugdrug interaction between nirmatrelvir/ritonavir and tacrolimus. Deuremidevir hydrobromide tablets (VV116) is an orally small molecule agents target SARS-CoV-2 RdRp and inhibits viral replication. It may have a low likelihood of drug-drug interactions and has a potential to provide new treatment option. We described three cases of renal transplant patients with concomitant impaired renal function who developed COVID-19 pneumonia and were treated with VV116. Despite varying degrees of drug accumulation, these patients achieved rapid viral clearance and showed prompt improvement in

    Keywords: COVID-19, organ transplant, Kidney dysfunction, Drug accumulation, VV116

    Received: 02 Oct 2024; Accepted: 30 Dec 2024.

    Copyright: © 2024 Zhang, Gao, Miao, Wang, Zhou, Gao, Liu, Wu, Ma, Zhou, Yang, Meng, Feng, Zhao, Liu, Mou, Kang, Liang and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zhongjie Hu, Liver Disease Center, Beijing You’An Hospital, Capital Medical University, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.